세계의 바이오의약품용 튜브 시장(2023-2030년)

Market Overview

The global biopharmaceutical tubing market reached US$ 3,580.4 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 6,674.2 million by 2030. The biopharmaceutical tubing market is expected to exhibit a CAGR of 8.3% during the forecast period (2023-2030). The launch and use of platinum-cured silicone tubing as a material of choice will likely emerge as a significant trend in the biopharmaceutical tuning market during the forecast period.

Thus, the players have significant opportunities to enter the biopharmaceutical tubing market with superior and cost-effective products. For instance, in January 2020, Watson-Marlow Fluid Technology Group (WMFTG) launched BioPure silicone transfer tubing to confer safe, reliable, and cost-effective solutions for a wide range of bioprocess fluid transfer applications.

Biopharmaceutical tubing is tear-resistant that is translucent. It is designed for use in manufacturing procedures for pharmaceutical and biotechnology products. Tubing utilized in pharmaceutical or biotech applications has certain specifications. When using extractable compounds, the capacity to endure sterilizing procedures and the transmission of positive test results.

The biopharmaceutical tubing market growth rate is high, owing to several factors including the rising adoption of silicone biopharmaceutical tubing due to the number of advantages these have over other materials, such as its ease of sterilization, inherent purity, pliability, and no side effects. The biopharmaceutical tubing market scope includes the type of biopharmaceutical tubing which include silicone, metal, or plastic or the applications of these tubing in various fields such as pharmaceutical and biopharmaceutical, clinical or research and development.

Market Dynamics

The increasing elderly population and strategic initiatives drive the growth of the biopharmaceutical tubing market

The global market for biopharmaceutical tubing is expanding as a result of the rising elderly population. The increase in life expectancy is leading to a rise in the geriatric population in the world. According to the World Health Organization (WHO), the global population share of people with age more than 60 would nearly double from 12% in 2015 to 22% in 2050.

According to the United Nations World Population Ageing Report, in 2017, there were 962 million people with age 60 or above in the world, and the number is expected to reach ~2.1 billion by 2050.

Additionally, strategic initiatives such as product launches, acquisitions, mergers, partnerships, or others will also provide lucrative growth to the market. For instance, in April 2021, concerning the potential of BioCardia Helix catheter biotherapeutics delivery products, BioCardia, Inc., a regenerative medicine developer company, entered into a contract with one of the top Japanese biotechnology firms. It is a non-exclusive, global license for the delivery of biotherapeutics using the BioCardia Helix catheter in particular cell types for cardiac reasons.

For manufacturers, the expanding R&D and technical breakthroughs open very significant expansion opportunities. Biopharmaceutical tubing has a huge biopharmaceutical tubing market opportunity since pharmaceutical and biopharmaceutical industries are increasingly using it to transport their substances or materials.

The growing research and development and technological advancements create lucrative growth prospects for manufacturers

There is a sizable market opportunity for biopharmaceutical tubing, as it is becoming more widely accepted in pharmaceutical and biopharmaceutical companies for the transportation of their compounds or materials. Manufacturers are going to have profitable choices for growth as demand for products like silicone or metal biopharmaceutical tubing will be required.

Silicone tubing and hoses can be used to convey the typical chemicals used in biopharmaceutical CIP (clean-in-place) or SIP (sterilize-in-place) operations. Tubing employed in pharmaceutical as well as biotech applications has certain specifications. The various varieties of silicone tubing are now being researched and developed, but before that can happen, the product must first satisfy the standards for usage in the medical industry, including non-toxicity and cleanliness.

Medical-grade silicone tubing attributes compound compositions that make it odorless, non-toxic, and tasteless. It must not have any tendency that supports bacterial growth. Hence, rising technological advancements or research and development are contributing to the growth of the market.

The disadvantages or limitations associated with the use of biopharmaceutical tubing

When processing products that contain any animal ingredients or compounds derived from animals, the majority of pharmaceutical and biopharmaceutical firms have encountered issues linked to animal ingredients and their possible effects on completed products. Tubing materials can occasionally react with industrial compounds.

Another potentially dangerous material is silicone oils. A residue may be left in the completed product as a result of the oils reacting with other ingredients. Poor welding and inner tube surfaces are the main causes of corrosion/contamination issues in pharmaceutical and biotech operations.

Given that the tubes and fittings make up 90% of the surface area in contact with the product fluid, these parts must be manufactured to make high-quality welding simple and consistent to ensure trouble-free manufacturing.

For more details on this report - Request for Sample

COVID-19 Impact Analysis

The COVID-19 analysis includes the Pre-COVID Scenario, COVID Scenario, and Post-COVID Scenario in addition to pricing dynamics (including pricing change during and after the pandemic evaluating it with pre-COVID scenarios), demand-supply spectrum (shift in demand and supply due to trading restrictions, lockdown, and afterwards issues), government initiatives (initiatives to reactivate a market, industry, or sector by government bodies), and manufacturers strategic initiatives.

Russia-Ukraine Conflict Analysis

The Russia-Ukraine conflict is estimated to have a low impact on the global biopharmaceutical tubing market, owing to the low number of key market players in this region. However, the impact of the import and export of raw materials is expected to have little influence over the global biopharmaceutical tubing market growth over the forecast period.

Segment Analysis

The global biopharmaceutical tubing market is segmented based on type, application and region.

Pharmaceutical and biopharmaceutical segment account for 50.8% of the biopharmaceutical tubing market share, owing to rising demand for tubing in biopharmaceuticals.

The pharmaceutical and biopharmaceutical industry is currently growing due to huge demands owing to the increasing population. Various product launches and formulations are taking place to meet the demand for several products utilizing biopharmaceutical tubing due to its various advantages and characteristics crucial for manufacturing.

Specialized tubing with high quality is crucial for designing an efficient pharmaceutical and biopharmaceutical system for fluid processing. One must take special considerations to avoid possible product contamination found within specific tube composites as residues.

Pharmaceutical and biopharmaceutical manufacturing usually involves batch sample retention and producing drug or substance specimens. These samples (liquid) are continuously stored in small bags with tubing attached. This tubing should be sealed permanently without breaking sterility, using heat and compression to prevent contamination and spillage.

Various key players are developing and launching novel products with the latest innovations. For instance, on May 18, 2022, Freudenberg Medical, a biopharmaceutical and clinical tubing and components manufacturer, introduced its high-purity thermoplastic elastomer tubing HelixFlex, developed for different biopharmaceutical and pharmaceutical applications.

Geographical Analysis

North America holds 40.1% of the market share owing to the strong presence of major players and increasing technological advancements.

Manufacturers have chances to expand their operations in this region because of the rising demand for biopharmaceutical tubing for several operations in bioprocessing and storage in North America. The area has many producers and suppliers, and its rapid economic development has increased the industrial production of biopharmaceutical tubing, which has increased the demand.

Growth is also fueled by rising technological advancements and novel product launches. For instance, the AdvantaPURE product portfolio of biopharmaceutical tubing includes various options in its series AdvantaFlex or AdvantaSil. It includes biopharmaceutical pump tubing, platinum-cured silicone tubing and reinforced tubing, and reinforced FEP, PTFE, and EPDM tubing.

AdvantaPURE develops tubing for different needs, such as high-pressure silicone tubing, low-temperature silicone tubing, and tubing specifically developed for the durability of pumping systems and tubing which enhance the pressure capabilities. The aforementioned elements show North America's supremacy on a worldwide scale.

Competitive Landscape

The major global players in the biopharmaceutical tubing market include W. L. Gore and Associates, Inc., Rehu Group (RAUMEDIC AG), Freudenberg Group (Freudenberg Medical), Genstar Capital (Tekni-Plex, Inc.), Holland Applied Technologies, Inc., DuPont de Nemours, Inc., Sartorius AG, Ami Polymer, Saint-Gobain and Nordson Corporation among others.

Why Purchase the Report?

• To visualize the global biopharmaceutical tubing- market segmentation based on type, application and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of biopharmaceutical tubing market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The global biopharmaceutical tubing market report would provide approximately 53 tables, 54 figures and 195 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Type
• 3.2. Snippet by Application
• 3.3. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Increasing Elderly Population and Strategic Initiatives
    • 4.1.1.2. Growing Application of Single-Use Systems (SUS)
  • 4.1.2. Restraints
    • 4.1.2.1. The Disadvantages or Limitations Associated With the Use of Biopharmaceutical Tubing
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Forces Analysis
• 5.2. Supply Chain Analysis
• 5.3. Unmet Needs
• 5.4. Regulatory Analysis

6. COVID-19 Analysis

• 6.1. Analysis of COVID-19
  • 6.1.1. Before COVID-19 Scenario
  • 6.1.2. Present COVID-19 Scenario
  • 6.1.3. Post COVID-19 or Future Scenario
• 6.2. Pricing Dynamics Amid COVID-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During Pandemic
• 6.5. Manufacturers Strategic Initiatives
• 6.6. Conclusion

7. By Type

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 7.1.2. Market Attractiveness Index, By Type
• 7.2. Silicone *
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Plastic
• 7.4. Metal

8. By Application

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 8.1.2. Market Attractiveness Index, By Application
• 8.2. Pharmaceutical and Biopharmaceutical *
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Clinical
• 8.4. Research and Development
• 8.5. Diagnosis

9. By Region

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 9.1.2. Market Attractiveness Index, By Region
• 9.2. North America
  • 9.2.1. Introduction
  • 9.2.2. Key Region-Specific Dynamics
  • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.2.5.1. The U.S.
    • 9.2.5.2. Canada
    • 9.2.5.3. Mexico
• 9.3. Europe
  • 9.3.1. Introduction
  • 9.3.2. Key Region-Specific Dynamics
  • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.3.5.1. Germany
    • 9.3.5.2. The U.K.
    • 9.3.5.3. France
    • 9.3.5.4. Italy
    • 9.3.5.5. Spain
    • 9.3.5.6. Rest of Europe
• 9.4. South America
  • 9.4.1. Introduction
  • 9.4.2. Key Region-Specific Dynamics
  • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.4.5.1. Brazil
    • 9.4.5.2. Argentina
    • 9.4.5.3. Rest of South America
• 9.5. Asia-Pacific
  • 9.5.1. Introduction
  • 9.5.2. Key Region-Specific Dynamics
  • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.5.5.1. China
    • 9.5.5.2. India
    • 9.5.5.3. Japan
    • 9.5.5.4. Australia
    • 9.5.5.5. Rest of Asia-Pacific
• 9.6. Middle East and Africa
  • 9.6.1. Introduction
  • 9.6.2. Key Region-Specific Dynamics
  • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application

10. Competitive Landscape

• 10.1. Competitive Scenario
• 10.2. Market Positioning/Share Analysis
• 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

• 11.1. W. L. Gore and Associates, Inc. *
  • 11.1.1. Company Overview
  • 11.1.2. Type Portfolio and Description
  • 11.1.3. Financial Overview
  • 11.1.4. Key Developments
• 11.2. DuPont de Nemours, Inc.
• 11.3. Freudenberg Group (Freudenberg Medical)
• 11.4. REHAU Group (Raumedic AG)
• 11.5. Genstar Capital LLC (TekniPlex)
• 11.6. Holland Applied Technologies, Inc.
• 11.7. Sartorius AG
• 11.8. Saint-Gobain
• 11.9. Ami Polymer
• 11.10. Nordson Corporation

LIST NOT EXHAUSTIVE

12. Appendix

• 12.1. About Us and Services
• 12.2. Contact Us